Medical genetics company Invitae released a first-of-its-kind data use transparency and impact report today detailing the impact of patient data on genetic research. The report comes as concerns about ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Genetic testing company Invitae has begun making its screening programs available at no charge for conditions including muscular dystrophy, prostate cancer, cardiomyopathy, arrhythmia and lysosomal ...

The rumors are true: A week after reports first surfaced that Invitae was on the brink of filing for bankruptcy, the genetic testing company has done exactly that. In a release it put out late Tuesday ...

Invitae (NYSE: NVTA) has been one of the most beaten-up stocks this year, falling more than 70% thus far (the S&P 500 has declined by only 10% over the same period). Significant losses and a growth ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...